Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Perspectives in the treatment of gastric cancer

Abstract

The overall 5-year survival of patients with gastric cancer is only 23% in the US compared with 60% in Japan. For Western patients, detecting the disease earlier and applying treatment quality control could substantially improve clinical outcome. For the treatment of gastric cancer, complete tumor resection, whenever feasible, is the standard treatment. Resection of the primary tumor (partial or total gastrectomy) is based on standardized criteria of the tumor, such as location, stage, histology, and surgical margins. The extent of regional lymphadenectomy required, however, has been a matter of considerable debate. Emerging evidence from the latest randomized controlled trials show that extended (D2) lymphadenectomy is safe and able to cure 20% of patients with N2-disease compared with 0% treated with limited D1 dissection, provided that the optimal surgical technique is used. Estimates suggest that this N2-specific subgroup advantage reflects a potential absolute overall survival benefit of 3–6%. Postoperative decisions about adjuvant chemotherapy and radiotherapy are based on pathologic staging, the extent of surgery performed (D0/D1 vs D2/D3) and the risk–benefit ratio. Recurrence-risk and mortality-risk reduction is achievable with a carefully planned relapse-prevention guided therapeutic strategy. Patient-related factors (tumor features and expected recurrence-risk magnitude) and treatment-related factors (surgical experience, adjuvant treatment risk–benefit ratio) should be considered on an individual basis. In future, genomic-based approaches will help to provide a more personalized therapeutic approach and improve patient outcome.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The extent of lymphadenectomy for subtotal gastrectomy in terms of dissection of lymph nodes.

Similar content being viewed by others

References

  1. Parkin DM et al. (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37 (Suppl 8): S4–S66

    Article  Google Scholar 

  2. Jemal A et al. (2004) Cancer Statistics, 2004. CA Cancer J Clin 54: 8–29

    Article  Google Scholar 

  3. Sasako M (2003) Principles of surgical treatment for curable gastric cancer. J Clin Oncol 21 (Suppl): S274–S275

    Article  Google Scholar 

  4. Fujii M et al. (1999) State of the art in the treatment of gastric cancer: from the 71st Japanese Gastric Cancer Congress. Gastric Cancer 2: 151–157

    Article  Google Scholar 

  5. Roukos DH (2000) Current status and future perspectives in gastric cancer management. Cancer Treat Rev 26: 243–255

    Article  CAS  Google Scholar 

  6. Bonenkamp JJ et al. (1993) Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. World J Surg 17: 410–415

    Article  CAS  Google Scholar 

  7. McCulloch PG et al. (1995) Comparison of the molecular genetics of c-erb-B2 and p53 expression in stomach cancer in Britain and Japan. Cancer 75: 920–925

    Article  CAS  Google Scholar 

  8. Noguchi Y et al. (2000) Is gastric carcinoma different between Japan and the United States? Cancer 89: 2237–2246

    Article  CAS  Google Scholar 

  9. Bonenkamp JJ et al. (1999) Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med 340: 908–914

    Article  CAS  Google Scholar 

  10. Cuschieri A et al. (1999) Patient survival after D1 and D2 resection for gastric cancer: long-term results of the MRC randomised surgical trial. Surgical Co-operative Group. Br J Cancer 79: 1522–1530

    Article  CAS  Google Scholar 

  11. Nashimoto A et al. (2003) Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 21: 2282–2287

    Article  CAS  Google Scholar 

  12. Degiuli M et al. (2004) Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 30: 303–308

    Article  CAS  Google Scholar 

  13. Wu CW et al. (2004) Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 91: 283–287

    Article  CAS  Google Scholar 

  14. Sano T et al. (2004) Gastric cancer surgery: Morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy–Japan Clinical Oncology Group Study 9501. J Clin Oncol 22: 2767–2773

    Article  Google Scholar 

  15. Hartgrink HH et al. (2004) Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 22: 2069–2077

    Article  CAS  Google Scholar 

  16. Hundahl SA et al. (2000) The National Cancer Data Base Report on poor survival of US gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer 88: 921–932

    Article  CAS  Google Scholar 

  17. Macdonald JS et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725–730

    Article  CAS  Google Scholar 

  18. Kappas AM et al. (2004) Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11: 727–730

    Article  Google Scholar 

  19. Roukos DH and Kappas AM (2001) Limitations in controlling risk of recurrence after curative surgery for advanced gastric cancer are now well-explained by molecular-based mechanisms. Ann Surg Oncol 8: 620–621

    Article  CAS  Google Scholar 

  20. Chambers AF et al. (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563–572

    Article  CAS  Google Scholar 

  21. Roukos DH et al. (2001) Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 84: 1602–1609

    Article  CAS  Google Scholar 

  22. Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 11: 127–129

    Article  Google Scholar 

  23. Kappas AM et al. (2003) Evidence-based approach: Is it time to change funding, research policy and treatment strategy of gastric cancer in the western world? Gastric Breast Cancer 2: 24–27

    Google Scholar 

  24. Greene FL et al. (2002) AJCC Cancer Staging Handbook, edn 6. New York: Springer-Verlag.

    Book  Google Scholar 

  25. Japanese Gastric Cancer Association (1998) Japanese classification of gastric cancer, 2nd English Edn. Gastric Cancer 1: 8–24

  26. Lordick F et al. (2004) Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 91: 540–551

    Article  CAS  Google Scholar 

  27. Mochiki E et al. (2004) Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 28: 247–253

    Article  Google Scholar 

  28. Dehdashti F and Siegel BA (2004) Neoplasms of the esophagus and stomach. Semin Nucl Med 34: 198–208

    Article  Google Scholar 

  29. Kappas AM and Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9: 828–830

    Article  Google Scholar 

  30. Siewert JR et al. (1998) Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228: 449–461

    Article  CAS  Google Scholar 

  31. Siewert JR et al. (2000) Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 232: 353–361

    Article  Google Scholar 

  32. Gunderson LL and Sosin H (1982) Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 8: 1–11

    Article  CAS  Google Scholar 

  33. Wanebo HJ et al. (1993) Cancer of the stomach: A patient care study by the American College of Surgeons. Ann Surg 218: 583–592

    Article  CAS  Google Scholar 

  34. Bozzetti F et al. (1999) Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 230: 170–178

    Article  CAS  Google Scholar 

  35. Nakajima T (2002) Gastric cancer treatment guidelines in Japan. Gastric Cancer 5: 1–5

    Article  Google Scholar 

  36. Yokota T et al. (2003) Treatment strategy of limited surgery in the treatment guidelines for gastric cancer in Japan. Lancet Oncol 4: 423–428

    Article  Google Scholar 

  37. Allum WH et al. (2002) Guidelines for the management of oesophageal and gastric cancer. Gut 50 (Suppl 5): S1–S23

    Article  Google Scholar 

  38. Maruyama K et al. (1987) Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 11: 418–425

    Article  CAS  Google Scholar 

  39. Gall FP and Hermaneck P (1985) New aspects in the surgical treatment of gastric carcinoma–a comparative study of 1,636 patients operated on between 1969 and 1982. Eur J Surg Oncol 11: 219–225

    CAS  PubMed  Google Scholar 

  40. Harrison LE et al. (1998) Total gastrectomy is not necessary for proximal gastric cancer. Surgery 123: 127–130

    Article  CAS  Google Scholar 

  41. Padera TP et al. (2002) Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296: 1883–1886

    Article  CAS  Google Scholar 

  42. Iriyama K et al. (1994) Results of combined resection of invaded organs in patients with potentially curable, advanced gastric cancer. Eur J Surg 160: 27–30

    CAS  PubMed  Google Scholar 

  43. Martin RC II et al. (2002) Achieving R0 resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection? J Am Coll Surg 194: 568–577

    Article  Google Scholar 

  44. Bunt AM et al. (1995) Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 13: 19–25

    Article  CAS  Google Scholar 

  45. Roukos DH et al. (1998) Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 123: 573–578

    Article  CAS  Google Scholar 

  46. Lorenz M et al. (2002) Preservation vs resection of the spleen for gastric cancer. Gastric Breast Cancer 1: 33–39

    Google Scholar 

  47. Birkmeyer JD et al. (2003) Surgeon volume and operative mortality in the United States. N Engl J Med 349: 2117–2127

    Article  CAS  Google Scholar 

  48. Panzini I et al. (2002) Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88: 21–27

    Article  CAS  Google Scholar 

  49. Bajetta E et al. (2002) Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 13: 299–307

    Article  CAS  Google Scholar 

  50. Goldhirsch A et al. (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21: 3357–3365

    Article  Google Scholar 

  51. Spira A and Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 350: 379–392

    Article  CAS  Google Scholar 

  52. Ott K et al. (2003) Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 6: 159–167

    Article  CAS  Google Scholar 

  53. Allum W et al. (2003) Perioperative chemotherapy in operable gastric and lower oesophageal cancer: A randomized, controlled trial (the MAGIC trial, ISRCTN 93793971) [abstract]. Proc Am Soc Clin Oncol 22: a998

    Google Scholar 

  54. Ajani JA et al. (2004) Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22: 2774–2780

    Article  CAS  Google Scholar 

  55. Yu W (2003) Impact of perioperative intraperitoneal chemotherapy on the treatment of primary gastric cancer. Surg Oncol Clin N Am 12: 623–634

    Article  Google Scholar 

  56. Glehen O et al. (2004) Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 5: 219–228

    Article  Google Scholar 

  57. Xu DZ et al. (2004) Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol 10: 2727–2730

    Article  Google Scholar 

  58. Gschwind A et al. (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4: 361–370

    Article  CAS  Google Scholar 

  59. Weiss MM et al. (2003) Genomic profiling of gastric cancer predicts lymph node status and survival. Oncogene 22: 1872–1879

    Article  CAS  Google Scholar 

  60. Kim MC et al. (2004) Lymphatic mapping and sentinel node biopsy using 99mTc tin colloid in gastric cancer. Ann Surg 239: 383–387

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dimitrios H Roukos.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roukos, D., Kappas, A. Perspectives in the treatment of gastric cancer. Nat Rev Clin Oncol 2, 98–107 (2005). https://doi.org/10.1038/ncponc0099

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0099

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing